Evidence map›Paper›PMID 27981463›Full record

Observational studyClinical rheumatology2017

Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.

Claudia Fabiani, Antonio Vitale, Giacomo Emmi, Giuseppe Lopalco, Lorenzo Vannozzi, Silvana Guerriero, Stefano Gentileschi, Daniela Bacherini, Rossella Franceschini, Bruno Frediani and 4 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Noninfectious uveitis: Management with biologic agents.Indian journal of ophthalmology · 2026
    Review
  4. Article
  5. Article
  6. Management of Severe Behçet's Disease.Current rheumatology reports · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Current status of pancreatic islet xenotransplantation.Clinical transplantation and research · 2025
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Claudia FabianiDepartment of Ophthalmology, Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy. claudia.fabiani@gmail.com.
Antonio VitaleResearch Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
Giacomo EmmiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Giuseppe LopalcoInterdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, Bari, Italy.
Lorenzo VannozziDepartment of Surgery and Translational Medicine, Eye Clinic, University of Florence, Florence, Italy.
Silvana GuerrieroDepartment of Ophthalmology and Otolaryngology, Bari University, Bari, Italy.
Stefano GentileschiResearch Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
Daniela BacheriniDepartment of Surgery and Translational Medicine, Eye Clinic, University of Florence, Florence, Italy.
Rossella FranceschiniOphthalmology and Neurosurgery Department, University of Siena, Siena, Italy.
Bruno FredianiResearch Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
Mauro GaleazziResearch Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
Florenzo IannoneInterdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, Bari, Italy.
Gian Marco TosiOphthalmology and Neurosurgery Department, University of Siena, Siena, Italy.
Luca CantariniResearch Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
University of Siena · ITUniversity of Bari Aldo Moro · ITUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to evaluate the role of interleukin (IL)-1 inhibitors anakinra (ANA) and canakinumab (CAN) in the treatment of Behçet's disease (BD)-related uveitis. Multicenter retrospective observational study includes 19 consecutive BD patients (31 affected eyes) received treatment with anti-IL-1 agents. Data were analyzed at baseline and at 3 and 12 months. The primary endpoint is the reduction of ocular inflammatory flares (OIF). The secondary endpoints are improvement of best corrected visual acuity (BCVA); reduction of macular thickness defined by optical coherence tomography (OCT) and of vasculitis identified with fluorescein angiography (FA); evaluation of statistically significant differences between patients treated with IL-1 inhibitors as monotherapy, subjects also administered with disease modifying anti-rheumatic drugs (DMARDs) and/or corticosteroids as well as between patients administered with IL-1 inhibitors as first line biologic treatment and those previously treated with TNF-α inhibitors. At 12 months, OIF significantly decreased from 200 episodes/100 patients/year to 48.87 episodes/100 patients/year (p < 0.0001). The frequency of retinal vasculitis identified by FA significantly decreased between baseline and 3- and 12-month follow-up visits (p < 0.0001 and p = 0.001, respectively). OIF rate was significantly higher in patients co-administered with DMARDs (81.8 episodes/100 patients/year) than in patients undergoing IL-1 inhibitors as monotherapy (0.0 episodes/100 patients/year) (p = 0.03). No differences were identified on the basis of corticosteroid use and between patients administered with IL-1 inhibitors as first line biologic approach or second line. Steroid dosage was significantly decreased at 12-month visit compared to baseline (p = 0.02). Treatment with IL-1 inhibitors is effective in the management of BD-related uveitis and provides a long-term control of ocular inflammation in refractory and long-lasting cases.

Indexed as

Adrenal Cortex HormonesAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntirheumatic AgentsBehcet SyndromeDrug Therapy, CombinationFemaleHumansInflammationInterleukin-1Interleukin 1 Receptor Antagonist ProteinMaleMiddle AgedRetinaAdrenal Cortex HormonesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntirheumatic AgentscanakinumabInterleukin-1Interleukin 1 Receptor Antagonist ProteinAnakinraBehçet’s diseaseCanakinumabTreatmentUveitis

Identifiers

PMID27981463
OpenAlexW2562844669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.